Deep Tech Startups

Nuclera develops eProtein Discovery, a benchtop protein screening system that uses cell-free protein synthesis and digital microfluidics to design, screen, characterize, and express proteins in-house. It serves research scientists working on antibody discovery and protein studies, including soluble, membrane, and antibody fragment targets.

2 investors

Nuntius develops programmable nanocarriers for drug delivery that can target tissues beyond the liver and utilize machine learning to optimize carrier performance. The company serves pharmaceutical and biotech organizations developing targeted therapeutics.

2 investors

Nusano produces medical radioisotopes using a patented particle acceleration technology and supplies them to drugmakers, hospitals, and clinics for use in next-generation cancer therapies (radiotherapeutics) and diagnostics. The company operates in the healthcare and life sciences supply chain and is building a production facility in West Valley City, Utah.

2 investors

Twindo converts iPhone/iPad scans, floor plans, and point clouds into accurate, editable CAD and BIM files for architectural and construction professionals. The platform uses LiDAR and proprietary 3D scanning technology to digitize physical spaces for design and building workflows.

2 investors

Octavia Carbon designs modular Direct Air Capture (DAC) systems that remove CO2 from the atmosphere and store it permanently in basaltic rock formations, offering carbon removal and offsetting services. Based in Kenya, it integrates its technology with the country's geothermal energy resources and partners with Cella for geological storage.

2 investors

Oran Dev Co (ODC) builds the Odyssey Platform, a sovereign distributed compute grid that combines software-defined 5G/6G RAN, environmental sensing, and edge AI inference into a single open-architecture stack. It targets the US government, national security agencies, and allied telecom operators requiring supply-chain assurance and controllable infrastructure.

2 investors

Offline Protocol builds a mesh networking software and network layer that lets apps and devices communicate, authenticate, and coordinate when the internet is unavailable, using BLE and WiFi Direct with encrypted sessions. It serves teams operating at the disconnected edge and developers building offline-capable apps.

2 investors

Onai is a research and development organization focused on advances across artificial intelligence, blockchain, cryptography, large-scale computation, and verified programming. The company brings together an interdisciplinary team to work on problems spanning AI, sciences, and economics.

2 investors

OncoRes Medical develops an intraoperative imaging technology that combines optical coherence tomography (OCT) and elastography to give surgeons real-time assessment of tissue microstructure at a resolution comparable to histology. The medical device company works with breast cancer surgeons and pathologists and is developing its technology for surgical use.

2 investors

OnePot is a tool for synthesizing molecules, with end-to-end encryption of users' molecular structures. It appears aimed at chemistry and drug discovery users who require confidentiality of their chemical data.

2 investors

OPENEDGES develops semiconductor IP for AI edge computing, including a deep learning accelerator for inference and a memory subsystem consisting of interconnect, memory controller, and PHY IP. Its products target chip designers building efficient edge AI systems.

2 investors

Ophidion is an early-stage CNS biopharmaceutical company developing a non-invasive carrier technology that delivers gene-silencing agents and other therapeutics across the blood-brain barrier into the brain. It is building a pipeline of disease-modifying and symptomatic treatments for neurodegenerative diseases, including Huntington's disease and cognition-related conditions.

2 investors

Optera develops event-based neuromorphic sensors and on-orbit and ground systems for space domain awareness, aimed at satellite operators, defence contractors, and research partners. Its technology targets faster, lower-power sensing to make space operations more resilient in contested and degraded environments.

2 investors

Optimeos develops a nanoparticle-based drug formulation and delivery platform (CINCs and LINCs) for complex biologics including mRNA, DNA, peptides, and proteins, targeting rare diseases, immunology, and metabolic conditions such as obesity. Its technology enables intracellular and long-acting delivery for pharmaceutical and biotech partners addressing challenges like tissue targeting and dosing profiles.

2 investors

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases (IRDs) and other retinal and refractive disorders. It focuses on genetic medicine aimed at preserving and restoring vision for patients with rare eye conditions.

2 investors

OrangeQS provides automated testing and characterization equipment and software for quantum chips with several to hundreds of qubits. The company serves quantum hardware developers in industry and research with turnkey solutions that accelerate the quantum chip development cycle.

2 investors

Orbital Sidekick operates hyperspectral imaging satellites and provides data analysis for commercial operators in energy, mining, and agriculture, as well as environmental monitoring and national security applications. Its offerings help detect operational risks, support sustainability initiatives, and expand situational awareness through georectified hyperspectral intelligence.

2 investors

Ordaōs uses AI and deep learning through its Design Engine to design novel mini-proteins and protein binders such as nanobodies for drug discovery. The company serves pharmaceutical and biologics researchers, combining generative machine-learning models with wet-lab protein expression and characterization.

2 investors

Origami Robotics develops hardware components, specifically gearboxes, to improve general-purpose robotic manipulation by addressing limitations of high-ratio designs in simulation-to-reality transfer and force feedback.

2 investors

Orikine Bio develops precision-engineered bi-specific cytokine therapies ("Foldikines") that reprogram immune signaling to treat severe autoimmune and inflammatory diseases. It is a biotechnology company operating a proprietary cytokine engineering platform.

2 investors

Orthofuse designs orthopedic implants and surgical systems using 3D printing technology for trauma and spinal procedures. The company targets orthopedic surgeons and hospitals to improve surgical outcomes and reduce procedure complexity.

2 investors

Osium AI develops an AI-powered platform that helps industry leaders accelerate materials innovation and discovery by optimizing experimentation and managing research data. The platform serves companies in the materials science, chemicals, and related industries seeking to improve material performance and sustainability.

2 investors

OTIV develops assisted, remote, and autonomous driving technology for rail vehicles, offering camera and perception systems for shunting, obstacle detection, fleet management, and full autonomy. It serves industrial companies, railway undertakings, infrastructure managers, and OEMs to improve safety and cost-efficiency of rail operations.

2 investors

Oureon Technologies builds advanced sensing systems—including radar, acoustic sensors, passive RF, and airspace awareness software—for defense, public safety, and critical infrastructure applications. It serves the US military, American cities, and allied nations.

2 investors